Luxiq 0.12% Foam 1X50 gm Mfg.by: Glaxo Smithkline USA.

IMPORTANT SAFETY INFORMATION for Prescription LUXIQ? Foam
Systemic absorption of topical corticosteroids has caused reversible hypothalamicpituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment.

As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.

In clinical studies, the most common adverse events associated with the use of LUXIQ? Foam were burning, stinging, or itching at the application site.

IMPORTANT: Keep the foam away from your eyes, as it will sting. If the foam gets into your eyes, rinse well with cold water. If the stinging continues, contact your doctor immediately.

WARNING: Flammable. Avoid fire, flame or smoking during and immediately following application.

Click Here for Prescribing Information